TAS2R5 screening reveals biased agonism that fails to evoke internalization and downregulation resulting in attenuated desensitization
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0315820 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Donghwa Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and the Center for Personalized Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, United Stat…. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Down-Regulation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
The bitter taste receptor type 5 (TAS2R5) is expressed on multiple cell types and appears to be a suitable target for novel agonist treatments across multiple therapeutic areas. Like most G protein coupled receptors (GPCRs), TAS2R5 undergoes functional desensitization with prolonged agonist exposure which could limit effectiveness. The net loss of cellular receptors (termed downregulation) is a prominent mechanism of long-term desensitization; we screened 13 agonists for downregulation of receptor protein in TAS2R5-transfected HEK-293T and airway smooth muscle cells in culture, searching for pathway selectivity favoring G protein coupling over downregulation. The benchmark agonist 1,10-phenanthroline (denoted T5-1) evoked as much as 75% downregulation of TAS2R5 protein expression with 18-24 hrs of agonist exposure, while an analogue of T5-1 (denoted T5-12) caused a 2-3 fold increase in expression. Functionally, T5-1 and T5-12 were found to be full agonists when measuring [Ca 2+ ] i or ERK1/2 stimulation. The T5-12 phenotype was found to be due to agonist-induced stabilization of the receptor confining it to the cell membrane with subsequent failure to undergo internalization and receptor degradation. This occurred despite normal (referenced to T5-1) GRK-mediated receptor phosphorylation and β-arrestin recruitment by T5-12. Consistent with the lack of downregulation, T5-12 evoked much less functional desensitization of the [Ca 2+ ] i (43% vs 78%) and ERK1/2 (64% vs > 95%) responses compared to T5-1, respectively. We conclude that TAS2R5 pathway signaling is malleable to a more favorable therapeutic profile by agonist-receptor interactions that preserve primary signaling and minimizes desensitization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine and the Center for Personalized Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, United States of America.
- Department of Molecular Pharmacology and Physiology, University of South Florida Morsani College of Medicine, Tampa, Florida, United States of America.
ORCID-Profile: Stephen B Liggett
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Kim, D., Strzelinski, H. R., & Liggett, S. B. (2025). TAS2R5 screening reveals biased agonism that fails to evoke internalization and downregulation resulting in attenuated desensitization. PLOS ONE. https://doi.org/10.1371/journal.pone.0315820
Vancouver
Kim D, Strzelinski HR, Liggett SB. TAS2R5 screening reveals biased agonism that fails to evoke internalization and downregulation resulting in attenuated desensitization. PLOS ONE. 2025. doi:10.1371/journal.pone.0315820
BibTeX
@article{Kim2025,
author = {Kim, Donghwa and Strzelinski, Hannah R and Liggett, Stephen B},
title = {TAS2R5 screening reveals biased agonism that fails to evoke internalization and downregulation resulting in attenuated desensitization},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0315820}
}
EUVIMED